Phase 1 N=32 COVID-19 Convalescent Plasma for Mechanically Ventilated Population
Covid-19
Primary: Participants With Serious Adverse Events. — 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
Hypercholesterolemia
Primary: Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -32.0; -3.3 Percent Change — p=<0.0001
Phase 3 N=513 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.6; 14.6 months — p=0.003
Phase 2 N=34 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Change From Baseline to Week 13 (Day 85) in Inflammatory Rasch-built Overall Disability Scale (iRODS) Score — 0.234; 0.181 score on a scale (logits)
Phase 3 N=45 Comparing NicoBloc to Nicotine Lozenges
Smoking Cessation · Nicotine Dependence
Primary: The Treatment Satisfaction Survey — 63.62; 64.67 score on a scale
Phase 2 N=24 Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant
Primary: Change in Depression Symptoms Measured by the Hamilton Depression Rating Scale- 21 Items — -3.0; -3.8; -3.9; -4.0 score on a scale — p=0.55
Phase 2 N=142 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Heart Failure With Preserved Ejection Fraction
Primary: Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 — 108.39; 106.27 percentage of baseline NT-proBNP — p=0.7923
Phase 2 N=156 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) — 18.3; 15.7 Percentage of participants
Phase 3 N=593 Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
COVID · COVID-19 · SARS-CoV-2
Primary: Ordinal Outcome Scale - Day 7 — 5; 5; 9; 13 Participants
N/A N=35 Study to Characterize Effects of Programming in SCS Patients Undergoing a Temporary Trial
Chronic Pain
Primary: Patient Comfort — 30 Participants
N/A N=90 Heart Rate Response to Regadenoson and Sudden Cardiac Death
Left Ventricular Systolic Dysfunction · Sudden Cardiac Death
Primary: Sudden Cardiac Death — 2; 6 Participants
N/A N=89 Clinical Study To Assess The Safety, Parameters And Efficacy For Procedures Using A Radiofrequency Device
Tissue Heating · Coagulation
Primary: Subject Satisfaction — 0; 6; 4; 2 Participants
Phase 2 N=100 Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
Blunt Chest Wall Trauma · Rib Fracture · Sternal Fracture
Primary: Opioid Requirement at 24 Hours Post-randomization — 38; 202 morphine milligram equivalents
Phase 4 N=20 Academic-Industrial Partnership for Translation of Acoustic Angiography
Signs and Symptoms
Primary: Sensitivity and Specificity
Phase 3 N=32,450 Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Binary Response — 73; 130 Participants — p=<0.001